Medivisor Inc. Announces Exclusive Distribution Rights in Italy for Albumax

HUNTINGTON STATION, NY--(Marketwire - September 18, 2008) - Medivisor Inc. (PINKSHEETS: MVSR) announced today that it has expanded its previously announced Albumax marketing agreement. Medivisor has signed an agreement giving Medivisor the exclusive right to distribute Albumax in Italy. Albumax, a whey protein isolate formula, makes it easy for Kidney disorder patients to reach their daily requirements of high quality protein in their diet. Medivisor anticipates consummating a distribution relationship in Italy shortly.

According to the National Kidney Foundation, 26 million Americans have Chronic Kidney Disease (CKD) and another 20 million more are at increased risk. The number of those affected worldwide is significantly higher. According to The Kidney Alliance, a UK organization and sponsor of World Kidney Day, worldwide, more than 500 million people are living with some form of kidney disease.

"Research we have conducted in Italy shows tremendous interest in Albumax," stated Dino Luzzi, CEO of Medivisor Inc. "In both the United States and Italy, our sales and distribution network has strong customer relationships, allowing us to leverage our existing distribution capabilities. We intend to use Italy as a starting point to launch the product throughout the rest of Europe."

About Medivisor Inc.: Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy, event management, public relations and market research. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of both pharmaceutical vendors as well as the practitioners.

About Cura Pharmaceutical Co. Inc.:

Cura Pharmaceutical Co. Inc. is a New Jersey-based pharmaceutical marketing company that focuses on select niche markets through the offering of specialty products and services. Cura's strategy is to provide products to the American Healthcare Practitioner and to create partnerships worldwide that satisfy a distinct unmet medical need and are cost effective. These products often are not readily accessible and provide enhancements to existing treatments. Cura's management team has extensive experience in the industry, with over 100 years of combined pharmaceutical experience.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact Information: Contact: Dino Luzzi CEO Medivisor Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100